Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

  1. ESMO
  2. Guidelines
  3. ESMO-MCBS
  4. ESMO-MCBS for Solid Tumours

ESMO-MCBS Scorecards

ESMO MCBS 1000x150

The ESMO-MCBS Scorecards provides a centralised location of cancer medicines that have been scored and published by ESMO.

It includes all cancer medicines approved by the European Medicines Agency (from January 2016) and the US Food and Drug Administration (from January 2020).

ESMO-MCBS Scores
Number of studies
Non-curative setting
5 17
4 116
3 131
2 41
1 23
NEB 4
Curative setting
A 46
C 3
NEB 1
ESMO-MCBS Scores by tumour type
Non-curative setting
Breast Cancer 38
Central Nervous System Malignancies 0
Endocrine Tumours 20
Gastrointestinal Cancers 62
Genitourinary Cancers 60
Gynaecological Malignancies 34
Head and neck cancer 12
Refractory NTRK fusion-positive cancers 2
Sarcoma 9
Skin Cancers 27
TMB-H solid tumours 1
Thoracic Malignancies 66
dMMR/MSI-H solid tumour 1
Curative setting
Breast Cancer 8
Central Nervous System Malignancies 1
Endocrine Tumours 0
Gastrointestinal Cancers 15
Genitourinary Cancers 3
Gynaecological Malignancies 0
Head and neck cancer 1
Refractory NTRK fusion-positive cancers 0
Sarcoma 2
Skin Cancers 12
TMB-H solid tumours 0
Thoracic Malignancies 4
dMMR/MSI-H solid tumour 0

The ESMO-MCBS Scorecards

The ESMO-MCBS Scorecards allows you to filter either by Agent, Tumour or Score giving priority to different criteria such as Agent and Tumour Type and Tumour sub-type and Tumour sub-group in the Curative or Non-curative setting. This content will be updated regularly and communicated to ESMO Members.

reset selection
Evaluation form 1  For new approaches to adjuvant therapy or new potentially curative therapies
Evaluation form 2a For therapies that are not likely to be curative with primary endpoint of OS with separate sheets for:
Evaluation form 2b For therapies that are not likely to be curative with primary endpoint PFS with separate sheets for:
Evaluation form 2c  For therapies that are not likely to be curative with primary endpoint other than OS or PFS or equivalent (non-inferiority) studies
Evaluation form 3  For single-arm studies in orphan diseases and for diseases with high unmet need when primary outcome is PFS or ORR.
To evaluate ESMO-MCBS score adjustments based on quality of life .

My watchlist

    Tested Agent(s) Combined Agent(s) Control Arm Treatment Setting Tumour Type Tumour Sub-type Tumour Sub-group Trial Name Ref. Score Scorecard Scorecard
    Pembrolizumab - Investigator’s choice of ChT (paclitaxel, docetaxel or vinflunine) Locally advanced or metastatic UC in adults who have received prior platinum-containing ChT MK-3475-045/KEYNOTE-045
    Genitourinary Cancers
    		 Urothelial Carcinoma - MK-3475-045/KEYNOTE-045

    4

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    FINAL SCORE

    • F2a
      4
    Nivolumab - Placebo Adjuvant therapy for adult patients with oesophageal or gastroesophageal junction cancer who have residual pathologic disease following prior neoadjuvant chemoradiotherapy CheckMate 577
    Gastrointestinal Cancers
    		 Oesophageal or gastroesophageal carcinoma - CheckMate 577

    A

    PRELIMINARY SCORE

    • DFS

    ADJUSTMENTS

    FINAL SCORE

    • F1

      A
    Sotorasib - Single arm Treatment of adults with advanced non-small cell lung cancer with KRAS G12C mutation and who have progressed after at least one prior line of systemic therapy CodeBreaK 100
    Thoracic Malignancies
    		 Non-small-cell Lung Cancer KRAS G12C mutated CodeBreaK 100

    3

    PRELIMINARY SCORE

    • ORR

    ADJUSTMENTS

    FINAL SCORE

    • F3
      3
    Cemiplimab - Single arm (Phase II) Treatment of basal cell carcinoma (laBCC or mBCC) who have progressed on or are intolerant to a hedgehog pathway inhibitor (HHI) Study 1620
    Skin Cancers
    		 Basal Cell Carcinoma - Study 1620

    3

    PRELIMINARY SCORE

    • ORR

    ADJUSTMENTS

    FINAL SCORE

    • F3
      3
    Nivo/Ipi (nivolumab and ipilimumab) - Single arm (Phase II) Adult patients with MMR-deficient or MSI-high mCRC after prior fluoropyrimidine-based combination ChT CheckMate142
    Gastrointestinal Cancers
    		 Colorectal Cancer dMMR or MSI-H CheckMate142

    3

    PRELIMINARY SCORE

    • ORR

    ADJUSTMENTS

    FINAL SCORE

    • F3
      3
    Pemetrexed Cisplatin Cisplatin In combination with cisplatin for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma EMPHACIS
    Thoracic Malignancies
    		 Pleural mesothelioma - EMPHACIS

    3

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    FINAL SCORE

    • F2a
      3
    Lenvatinib Pembrolizumab Sunitinib Treatment of adults with advanced renal cell carcinoma in combination with pembrolizumab as first-line treatment CLEAR
    Genitourinary Cancers
    		 Renal cell cancer - CLEAR

    4

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    FINAL SCORE

    • F2b
      4
    Pembrolizumab ChT (paclitaxel + carboplatin) Placebo plus ChT (paclitaxel + carboplatin) In combination with ChT as neoadjuvant treatment and then continued as monotherapy as adjuvant treatment after surgery, is indicated for the treatment of adults with locally advanced, or early‑stage triple‑negative breast cancer at high risk of recurrence KEYNOTE-522
    Breast Cancer
    		 Early Breast Cancer Triple-negative KEYNOTE-522

    A

    PRELIMINARY SCORE

    • DFS

    ADJUSTMENTS

    FINAL SCORE

    • F1

      A
    Enfortumab vedotin - Investigator-chosen ChT (standard docetaxel, paclitaxel or vinflunine) Treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a platinum-containing chemotherapy and a programmed death receptor-1 or programmed death-ligand 1 inhibitor EV-301
    Genitourinary Cancers
    		 Urothelial Carcinoma - EV-301

    4

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    FINAL SCORE

    • F2a
      4
    Infigratinib - Single arm (Phase II) Previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement CBGJ398X2204
    Gastrointestinal Cancers
    		 Cholangiocarcinoma FGFR2 CBGJ398X2204

    3

    PRELIMINARY SCORE

    • ORR

    ADJUSTMENTS

    FINAL SCORE

    • F3
      3
    Pembrolizumab - Single arm (Phase II) Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy KEYNOTE-057
    Genitourinary Cancers
    		 Urothelial Carcinoma - KEYNOTE-057

    3

    PRELIMINARY SCORE

    • ORR

    ADJUSTMENTS

    FINAL SCORE

    • F3
      3
    Nivolumab Fluoropyrimidine and platinum ChT (FOLFOX or CAPOX) ChT (FOLFOX or CAPOX) First-line treatment for patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer and oesophageal adenocarcinoma CheckMate 649
    Gastrointestinal Cancers
    		 Gastric or gastroesophageal junction cancer and oesophageal adenocarcinoma - CheckMate 649

    1

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    FINAL SCORE

    • F2a
      1
    Nivolumab Fluoropyrimidine and platinum ChT (FOLFOX or CAPOX) ChT (FOLFOX or CAPOX) First‑line treatment for patients with HER2‑negative advanced or metastatic gastric, gastroesophageal junction or oesophageal adenocarcinoma whose tumours express PD-L1 with a CPS ≥5 CheckMate 649
    Gastrointestinal Cancers
    		 Gastric or gastroesophageal junction cancer and oesophageal adenocarcinoma HER2- PD-L1 CPS ≥5 CheckMate 649

    4

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    FINAL SCORE

    • F2a
      4
    Pralsetinib - Single arm Treatment for adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA-approved test ARROW
    Thoracic Malignancies
    		 Non-small-cell Lung Cancer RET fusion-positive ARROW

    3

    PRELIMINARY SCORE

    • ORR

    ADJUSTMENTS

    FINAL SCORE

    • F3
      3
    Pralsetinib - Single arm Treatment for adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC) not previously treated with a RET inhibitor ARROW
    Breast Cancer
    		 Non-small-cell Lung Cancer RET fusion-positive ARROW

    3

    PRELIMINARY SCORE

    • ORR

    ADJUSTMENTS

    FINAL SCORE

    • F3
      3
    Pembrolizumab - Single arm cohort study Patients with unresectable or metastatic dMMR/MSI-H solid tumours that have progressed following prior treatment and have no alternative treatment options KEYNOTE-158 - Cohort K
    dMMR/MSI-H solid tumour
    		 - dMMR/MSI-H KEYNOTE-158 - Cohort K

    3

    PRELIMINARY SCORE

    • ORR

    ADJUSTMENTS

    FINAL SCORE

    • F3
      3
    Trastuzumab ChT (cisplatin + capecitabine or 5-FU) ChT HER2-positive metastatic adenocarcinoma of the stomach or gastroesophageal junction in patients who have not received prior anti-cancer treatment for their metastatic disease ToGA
    Gastrointestinal Cancers
    		 Stomach or gastroesophageal junction cancer HER2+ ToGA

    3

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    FINAL SCORE

    • F2a
      3
    Ivosidenib - Placebo For adult patients with locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 mutation who were previously treated by at least one prior line of systemic therapy. ClarIDHy
    Gastrointestinal Cancers
    		 Cholangiocarcinoma IDH1 ClarIDHy

    3

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    FINAL SCORE

    • F2b
      3
    Mobocertinib - Single arm Locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations, with progression on or after platinum-based ChT Study 101
    Thoracic Malignancies
    		 Non-small-cell Lung Cancer EGFR+ exon 20 insertion mutations Study 101

    2

    PRELIMINARY SCORE

    • ORR

    ADJUSTMENTS

    FINAL SCORE

    • F3
      2
    Tisotumab vedotin - Single arm (Phase II) Adult patients with recurrent or metastatic cervical cancer with disease progression on or after ChT innovaTV 204
    Gynaecological Malignancies
    		 Cervical Cancer - innovaTV 204

    2

    PRELIMINARY SCORE

    • ORR

    ADJUSTMENTS

    FINAL SCORE

    • F3
      2
    Trifluridine/Tipiracil (TAS-102) - Placebo As monotherapy for the treatment of adult patients with metastatic colorectal cancer (CRC) who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-VEGF agents, and anti EGFR agents RECOURSE
    Gastrointestinal Cancers
    		 Colorectal Cancer - RECOURSE

    3

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    FINAL SCORE

    • F2a
      3
    Pembrolizumab - ChT ((5-fluorouracil–based therapy with or without bevacizumab or cetuximab) First‑line treatment of metastatic microsatellite instability‑high (MSI‑H) or mismatch repair deficient (dMMR) colorectal cancer in adults. KEYNOTE-177
    Gastrointestinal Cancers
    		 Colorectal Cancer dMMR or MSI-H KEYNOTE-177

    4

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    FINAL SCORE

    • F2b
      4
    Cabozantinib - Placebo Treatment of adult patients with locally advanced or metastatic differentiated thyroid carcinoma, refractory or not eligible to radioactive iodine who have progressed during or after prior systemic therapy COSMIC-311
    Endocrine Tumours
    		 Thyroid cancer - differentiated - COSMIC-311

    2

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    FINAL SCORE

    • F2b
      2
    Pralsetinib - Single arm Adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant MTC who require systemic therapy ARROW
    Endocrine Tumours
    		 Thyroid Cancer - medullary RET-mutant ARROW

    3

    PRELIMINARY SCORE

    • ORR

    ADJUSTMENTS

    FINAL SCORE

    • F3
      3
    Pralsetinib - Single arm Adult and paediatric patients 12 years of age and older with advanced or metastatic RETfusion-positive thyroid cancer who require systemic therapy and who are RAI-refractory ARROW
    Endocrine Tumours
    		 Thyroid cancer - differentiated RET fusion-positive ARROW

    3

    PRELIMINARY SCORE

    • ORR

    ADJUSTMENTS

    FINAL SCORE

    • F3
      3
    Atezolizumab - Best supportive care Adjuvant treatment following resection and platinum-based ChT for adult patients with Stage II to IIIA NSCLC whose tumors have PD-L1 expression on ≥1% of tumor cells IMpower010
    Thoracic Malignancies
    		 Non-small-cell Lung Cancer PD-L1 ≥1% IMpower010

    A

    PRELIMINARY SCORE

    • DFS

    ADJUSTMENTS

    FINAL SCORE

    • F1

      A
    Pembrolizumab ChT with our without bevacizumab Placebo + ChT with our without bevacizumab Persistent, recurrent, or metastatic cervical cancer in adults whose tumours express PD-L1 with a CPS ≥1 KEYNOTE-826
    Gynaecological Malignancies
    		 Cervical Cancer PD-L1 (CPS ≥1) KEYNOTE-826

    4

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    FINAL SCORE

    • F2a
      4
    Abemaciclib Standard endocrine therapy (aromatase inhibitors and/or antiestrogens with or without ovarian suppression) Standard endocrine therapy In combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor positive, HER2- negative, node positive early breast cancer at high risk of recurrence and a Ki-67 score >20% In pre or perimenopausal women, aromatase inhibitor endocrine therapy should be combined with a luteinising hormone-releasing hormone agonist monarchE
    Breast Cancer
    		 Early Breast Cancer HR+ HER2- node-positive Ki-67 score ≥20% monarchE

    A

    PRELIMINARY SCORE

    • DFS

    ADJUSTMENTS

    FINAL SCORE

    • F1

      A
    Pembrolizumab Cisplatin and 5-FU Placebo + cisplatin and 5-FU First-line treatment locally advanced or metastatic oesophageal or gastroesophageal junction carcinoma that is not amenable to surgical resection or definitive CRT in combination with platinum- and fluoropyrimidine-based ChT KEYNOTE-590
    Gastrointestinal Cancers
    		 Oesophageal or gastroesophageal carcinoma HER2- GEJ (all randomized) KEYNOTE-590

    3

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    FINAL SCORE

    • F2a
      3
    Pembrolizumab Platinum and fluoropyrimidine-based chemotherapy Placebo + cisplatin and 5-FU Pembrolizumab in combination with platinum and fluoropyrimidine-based chemotherapy, is indicated for the first-line treatment of locally advanced unresectable or metastatic carcinoma of the oesophagus in adults whose tumours express PD-L1 with a CPS ≥ 10 KEYNOTE-590
    Gastrointestinal Cancers
    		 Oesophageal Cancer PD-L1 CPS ≥10 KEYNOTE-590

    4

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    FINAL SCORE

    • F2a
      4

    This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

    For more detailed information on the cookies we use, please check our Privacy Policy.

    Customise settings

    • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.